Comparative Pharmacology
Head-to-head clinical analysis: PROPULSID versus PROPULSID QUICKSOLV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPULSID versus PROPULSID QUICKSOLV.
PROPULSID vs PROPULSID QUICKSOLV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT4 receptor agonist that enhances release of acetylcholine in the myenteric plexus of the gastrointestinal tract, increasing gastrointestinal motility.
Selective serotonin 5-HT4 receptor agonist; enhances release of acetylcholine in the enteric nervous system, increasing gastrointestinal motility without increasing gastric acid secretion.
10 mg orally three times daily, 15 minutes before meals and at bedtime. Maximum dose 20 mg four times daily.
10 mg orally three times daily before meals. Maximum 20 mg per dose.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (mean 7-10 hours) in healthy individuals; prolonged to 15-20 hours in hepatic impairment or with CYP3A4 inhibitors.
Terminal elimination half-life is approximately 6–12 hours in adults; prolonged in hepatic impairment (up to 20–30 hours) and elderly.
Primarily metabolized in the liver via CYP3A4; approximately 35-45% excreted in urine as metabolites and unchanged drug (<10% unchanged), and 45-60% in feces via biliary elimination.
Approximately 60-70% of a dose is excreted in urine as unchanged drug and metabolites; ~30% in feces via biliary excretion.
Category C
Category C
Gastroprokinetic Agent
Gastroprokinetic Agent